NEUROMARK system, which includes biofeedback monitoring features and advanced algorithmic controls, is a novel multi-point nerve disruption treatment for chronic rhinitis
Neurent Medical has secured approval from the US Food and Drug Administration (FDA) for its NEUROMARK Rhinitis Neurolysis Therapy (RNT).
The in-office treatment allows clinicians to disrupt posterior nasal nerves by creating lesions in patients with chronic rhinitis.
NEUROMARK system, which includes biofeedback monitoring features and advanced algorithmic controls, is a novel multi-point nerve disruption treatment for chronic rhinitis.